drugset / Trial / NCT04948827
A First-in-Human Study of SBP-9330 in Healthy Subjects
Phase 1
Completed
90 enrolled
Camino Pharma, LLC
National Institute on Drug Abuse (NIDA) · collabSanford Burnham Prebys · collabUniversity of California, San Diego · collab
RandomizedParallel-groupDouble-blindTreatment
Summary
This is a single center, first-in-human, randomized, double-blind, placebo-controlled, Single-Ascending Dose (SAD) / Multiple-Ascending Dose (MAD) study incorporating a food-effect cohort.
Timeline
- Start
- 2021-07-20
- Primary completion
- 2023-03-06
- Completion
- 2023-03-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | SBP-9330 | Unknown | 150 mg | Oral |
| Subject | SBP-9330 | Unknown | 225 mg | Oral |
| Subject | SBP-9330 | Unknown | 300 mg | Oral |
| Subject | SBP-9330 | Unknown | 450 mg | Oral |
| Subject | SBP-9330 | Unknown | 600 mg | Oral |
Indications
No indication recorded.